AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.
A live audio webcast will be accessible via AbbVie’s Investor Relations website at investors.abbvie.com, and an archived edition of the session will be available later the same day.
Positive
- None.
Negative
- None.
News Market Reaction – ABBV
In the Jan 5 session, ABBV declined 3.98%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Clinical data update | Positive | -0.3% | New ASH 2025 data across multiple blood cancers with strong efficacy signals. |
| Nov 24 | Conference appearance | Neutral | -2.9% | Piper Sandler healthcare conference fireside chat and webcast scheduling details. |
| Nov 18 | FDA approval | Positive | -0.1% | U.S. FDA approval of EPKINLY combo for relapsed or refractory follicular lymphoma. |
| Nov 14 | Awareness initiative | Positive | +0.0% | Launch of ‘Second Winds’ film highlighting lives of people with blood cancer. |
| Nov 13 | Patient support program | Positive | -0.4% | Announcement of 20 Migraine Career Catalyst Award recipients and support grants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including positive clinical and regulatory updates, has often coincided with flat-to-negative 24-hour price reactions, indicating a tendency for subdued or contrarian trading around announcements.
Over the past few months, AbbVie issued several notable updates. In November 2025, it received U.S. FDA approval for EPKINLY in follicular lymphoma after strong Phase 3 data, yet the stock was little changed. The company also highlighted oncology data for multiple blood cancers at ASH 2025, announced a patient-focused blood cancer film, and ran a migraine career award program. Multiple investor and healthcare conference appearances framed these developments for the market, but short-term price moves remained modest or negative.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Media: Gabby Tarbert (224) 244-0111 | Investors: Liz Shea (847) 935-2211 |
View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302652210.html
SOURCE AbbVie